Laurus Labs · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Sequential decline in CDMO despite management's Q1 guidance for improvement; timing of customer deliveries remains volatile and dependent on partner requests. Analyst Rohit Jain pressed management on why the expected sequential recovery did not materialize.
EBITDA margins at 15.4% remain significantly below historical 25%+ levels due to underutilized new capacities and INR 16 crore spent on new initiatives (CGT). Analyst Ranvir Singh questioned whether 20% full-year margin is achievable given H1 performance.
Management acknowledged pricing pressures in African ARV markets and noted that both ARV API and formulations will 'attain peak revenues soon.' NACO tender win (20% share) is positive but represents a new market rather than offsetting pricing declines.
Animal health business driven by a single large customer contract; any disruption or loss of this customer could materially impact the synthesis division's recovery timeline.
